India’s Ministry of Health recently released the “Report of the First National Anti-Tuberculosis Drug Resistance Survey”. According to the report, the survey is the largest national drug-resistant (DR) TB survey ever conducted by any country in the world. The survey results reveal that more than 6% of all TB patients in India have multidrug-resistant TB (MDR-TB).
For World TB Day 2018, we celebrate the courage and endurance of four MSF patients who are currently undergoing treatment for drug-resistant TB (DR-TB).
Pooja, Rekha, Vikas and Sita are receiving care in MSF’s DR-TB programme in Mumbai, where a multi-disciplinary MSF team is providing patients with resistant strains of TB with individual regimens of drugs are tailored according to their individual needs. This includes a combination of the two newest DR-TB drugs, bedaquiline and delamanid as part of their treatment regimen.
Despite being curable, the world is losing the battle against tuberculosis (TB). The road ahead is rife with challenges, from diagnosis to treatment, for patients and treatment providers alike.
In this Q&A, Dr. Francis Varaine, leader of the MSF working group on Tuberculosis, explains MSF’s priorities over the next ten years.
Moscow/Geneva, 15 November 2017 — Ahead of the first-ever Global Ministerial Conference on ‘Ending TB’ in Moscow, the international medical humanitarian organisation Doctors Without Borders/Médecins Sans Frontières (MSF) and the Stop TB Partnership called for countries with high burdens of tuberculosis (TB) to implement the latest international treatment and testing standards by World TB Day, 24 March 2018.
MSF urges governments to step up the use of newer TB drugs
Guadalajara, Mexico, October 13, 2017 - People with multidrug-resistant tuberculosis (MDR-TB) are still not receiving two newer TB drugs, bedaquiline and delamanid, which have been available for more than four years and have shown improved cure rates for the disease, deplored Doctors Without Borders/Médecins Sans Frontières (MSF) at the 48th Union World Conference on Lung Health in Guadalaja
India does not implement six out of the 16 key World Health Organisation (WHO)- recommended tuberculosis (TB) control policies in diagnosis, patient care and treatment, a new global report has found.
Four other policies that are a part of the national policy are not being fully implemented.
India’s tuberculosis control programme is not fully equipped to prevent, diagnose, and treat patients. The Revised National Tuberculosis Control Program uses outdated diagnostic techniques, suffers from repeated medicine stock-outs and lacks capacity to counsel tuberculosis patients, according to the Out of Step report released by the Stop TB Partnership and Médecins Sans Frontières last week.
Hamburg/Geneva, 5 July 2017 — Two days ahead of the G20 summit in Germany, the international medical humanitarian organisation Doctors Without Borders/Médecins Sans Frontières (MSF) and the Stop TB Partnership released the third edition of ‘Out of Step,’ a report highlighting the need for governments to increase efforts to combat tuberculosis (TB). The report reviews TB policies and practices in 29 countries – which account for 82% of the global TB burden – and shows that countries can do much more to prevent, diagnose and treat people affected by TB.
Bedaquiline may be the answer to several drug-resistant patients in India, but the government is extra cautious about the rollout. The drug has been approved for only 600 patients for a six-month regime. Shahida is one among over 200 patients selected so far including 68 in Mumbai.
While India houses the largest number – 27% – of the world’s 10.4 million new TB patients, Mumbai is the epicentre of the disease in the country. The metropolis has many overcrowded slums where about five people share a house like that of Patil’s. Such spaces are ideal for the TB bacteria to spread.